Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 30, 2026 - P2 | N=117 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2026 ➔ Mar 2027
Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • KRAS • PD-L1 • ROS1
|